|
Academic/Biomedical Research
News & Jobs
|
|
|
|
|
|
|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Company Profiles
Research Store
Research Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
10/6/2011 9:43:51 AM
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc., the world leader in rational genome engineering, today announced that it has filed a lawsuit against Cellectis SA and its affiliates Cellectis bioresearch and Cellectis bioresearch Inc. in the U.S. District Court for the Eastern District of North Carolina. The lawsuit seeks a ruling that Cellectis’ manufacture, use and sale of certain engineered meganucleases infringe U.S. Patent No. 8,021,867, a recently-issued patent related to Precision’s Directed Nuclease EditorTM (DNE) meganuclease technology. The lawsuit requests monetary damages as well as a permanent injunction preventing Cellectis from making, using, selling, offering for sale, or importing infringing engineered meganucleases in the United States.
|
|
|
|
|
|
|
|
|
|
|